Aclaris Therapeutics (ACRS) Total Liabilities (2014 - 2026)

Aclaris Therapeutics' Total Liabilities history runs 13 years deep, the most recent figure standing at $55.1 million for Q1 2026.

• In Q1 2026, Total Liabilities rose 1.93% year-over-year to $55.1 million; the TTM figure through Mar 2026 stood at $55.1 million (up 1.93% YoY), while the FY2025 annual figure was $57.4 million, down 11.42% from the prior year.
• Total Liabilities for Q1 2026 stood at $55.1 million, down from $57.4 million in the prior quarter.
• The five-year high for Total Liabilities was $64.8 million in Q4 2024, with the low at $27.2 million in Q2 2024.
• The 5-year median for Total Liabilities is $54.0 million (2025), against an average of $50.6 million.
• The sharpest annual moves came in 2024 and 2025: Total Liabilities tumbled 51.25% in 2024, then jumped 110.68% in 2025.
• Aclaris Therapeutics' Total Liabilities stood at $57.0 million in 2022, then retreated by 29.4% to $40.2 million in 2023, then soared by 61.02% to $64.8 million in 2024, then fell by 11.42% to $57.4 million in 2025, then declined by 4.02% to $55.1 million in 2026.
• Business Quant data shows ACRS's Total Liabilities at $55.1 million in Q1 2026, $57.4 million in Q4 2025, and $55.4 million in Q3 2025.